A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin, Administered Orally Once Daily, in Combination With Insulin Therapy for 24 Weeks in Chinese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 22 Dec 2017 Planned End Date changed from 24 Aug 2018 to 30 Nov 2018.
- 22 Dec 2017 Planned primary completion date changed from 24 Aug 2018 to 23 Nov 2018.
- 10 Jun 2017 Biomarkers information updated